Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Search results for
Congresnieuws 30/04/2019

ECCMID 2019

From April 13th - 16th, Amsterdam hosted the 29th European Congress of Clinical Microbiology & Infectious Diseases. With thousands of abstracts being discussed, it was easy to miss out on some developments. Invasive fungal diseases still pose many diagnostic and therapeutic challenges. Therefore, MEDtalks asked several top experts to come up with their personal (congress) highlights regarding this challenging topic, and focus on translating scientific developments to clinical practice. Topics and speakers Impact of new immunomodulators on the risk and management of invasive fungal infections by prof. Dimitrios Kontoyiannis, MD, PhD Management of invasive fungal infections by prof. Johan Maertens, MD, PhD New ESCMID guideline on invasive fungal infections by prof. Cornelia Lass-Flörl, MD, PhD The diagnosis of invasive fungal infections by prof. Katrien Lagrou, PharmD, PhD  

Congresnieuws 25/04/2019

ECCMID 2019: new guideline on invasive fungal infections

A dedicated working group of the European Society of Clinical Microbiology and Infectious Diseases is developing a new guideline on invasive fungal infections, which could be of particular relevance for the ICU population. Despite the guideline still being in an early phase, prof. Cornelia Lass-Flörl, who is actively involved in this new guideline, was eager to share some details on the background, methodology, contents, usefulness and expected timelines of this guideline.    This editorially independent interview has been financially sponsored by Gilead.

Congresnieuws 25/04/2019

ECCMID 2019: immunomodulators and invasive fungal infections

Oncology treatment has come a long way. Prof. Dimitrios Kontoyiannis first discusses the recent changes in oncology treatment and their respective impact on the risk of invasive fungal infections. Then he adresses which emerging patient populations in the (hemato-)oncology setting are at an increased risk of infections. How do we properly identify them and what are the challenges in treatment of these patients?   This editorially independent interview has been financially sponsored by Gilead.

Congresnieuws 25/04/2019

ECCMID 2019: management of invasive fungal infections

Managing invasive fungal diseases is a dynamic expertise. In this interview, prof. Johan Maertens talks about the changing fungal landscape, both in terms of the host (i.e. haematological patients) as the type of fungal pathogen. Looking at these changes: what are the relevant challenges and therapeutic opportunities?   This editorially independent interview has been financially sponsored by Gilead.

Congresnieuws 25/04/2019

ECCMID 2019: the diagnosis of invasive fungal infections

Invasive fungal diseases still pose many diagnostic challenges. MEDtalks asked prof. Katrien Lagrou to elaborate on some challenges that particularly concerned her, and to scour the ECCMID 2019 program for interesting (future) diagnostic developments.   This editorially independent interview has been financially sponsored by Gilead.

Nascholingen 04/03/2019

E-learning: Update on Renal cell carcinoma with prof. Camillo Porta

During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC.  ‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities.  Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’ Topics that are discussed in this e-learning are: When are we ready for adjuvant therapy? What is the role of cytoreductive nephrectomy in mRCC? How to choose from the available options for first, second, and third line treatment? What may be the impact of immunotherapy and novel TKIs on the treatment algorithm? Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL